Irene Brusa first saw the bright red arrows on the scan of a 76-year-old man from Bologna—tiny flares of activity in his prostate that MRI had missed. The man’s PSA level was high, but his MRI showed nothing clear. Still, something was wrong. That’s when the team at IRCCS Azienda Ospedaliero-Universitaria di Bologna turned to a new method: using PSMA PET/CT scans to guide biopsies. What they found changed everything.
Prostate cancer is tricky. While MRI scans help doctors spot dangerous tumors, up to 30% of serious cancers can slip through when results are unclear or negative. For years, men in this gray zone faced repeated, often painful biopsies—or worse, no diagnosis at all. But now, a study led by Dr. Andrea Farolfi in Bologna shows a better way. By using a special type of scan called PSMA PET/CT, doctors can pinpoint suspicious areas and guide biopsies directly to them.
The study followed 63 men whose MRI results were inconclusive. Each received a PSMA PET/CT scan using a tracer called 68Ga-PSMA-11. Then, doctors performed both targeted and standard systematic biopsies. The results were striking. Targeted biopsies found clinically significant prostate cancer in 37% of the men—almost twice as many as the 21% detected by standard biopsies alone. When both methods were combined, the detection rate jumped to 41%. That means more men got the diagnosis they needed, faster.
Even more promising: the scan’s signal strength, measured by SUVmax, was closely linked to aggressive cancer. In 11 patients, dynamic total-body PET scans revealed unique patterns in how tumors absorbed the tracer—clues that could help distinguish dangerous cancers from harmless ones. One patient’s SUVmax hit 55.6, a red flag that led directly to a correct diagnosis of ISUP 4 cancer, a serious form of the disease.
This isn’t just about better technology—it’s about better outcomes. Every missed cancer can mean delayed treatment. Every unnecessary biopsy carries risk. This new approach helps doctors do both: catch more dangerous cancers and avoid over-treating slow-growing ones. While the study was done in one center, its results are strong enough to spark change.
If larger studies confirm these findings, PSMA PET/CT could become a standard next step after a murky MRI. For men caught in diagnostic limbo, that could mean fewer guesses, fewer procedures, and more peace of mind. As Dr. Farolfi puts it, this method could make prostate cancer diagnosis not just more accurate, but truly personalized.